Stockscreener 앱 받기
59.93
3.21%
-2.13
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
BlackRock, Inc. Reduces Stake in BioMarin Pharmaceutical Inc. - GuruFocus
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo
10 Analysts Assess Biomarin Pharmaceutical: What You Need To Know - Benzinga
Goldman Sachs Adjusts Price Target for Biomarin Pharmaceutical ( - GuruFocus
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - Insider Monkey
Biomarin Pharmaceutical (BMRN) Price Target Lowered by Citigroup - GuruFocus
BioMarin Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Cantor maintains BioMarin stock overweight with $90 target By Investing.com - Investing.com South Africa
BioMarin's First-Quarter Earnings & Sales Beat Estimates - TradingView
BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView
Cantor maintains BioMarin stock overweight with $90 target - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
BioMarin’s Strong Q1 2025 Performance and Growth Outlook - TipRanks
BioMarin Pharmaceutical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioMarin (BMRN) Reports Strong Q1 2025 Growth and Strategic Adva - GuruFocus
Biomarin Pharma earnings beat by $0.43, revenue topped estimates - Investing.com India
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Earnings call transcript: BioMarin beats Q1 2025 forecasts, stock rises after hours - Investing.com
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates - Nasdaq
BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets - Yahoo Finance
BMRN Q1 Revenue Surpasses Expectations with Strong Product Deman - GuruFocus
BioMarin: Q1 Earnings Snapshot - News-Times
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Rise - marketscreener.com
BioMarin Pharmaceutical Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BMRN) - Seeking Alpha
Biomarin Pharmaceutical Inc. Q1 Profit Increases, Beats Estimates - Nasdaq
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance - PR Newswire
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin Pharmaceutical Inc expected to post earnings of 71 cents a shareEarnings Preview - TradingView
BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings - Barchart.com
Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment? - simplywall.st
20 Takeover Rumors Hedge Funds Are Buying - Insider Monkey
BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo
Implied Volatility Surging for BioMarin Stock Options - Yahoo Finance
Oppenheimer maintains BioMarin stock Outperform with $98 target By Investing.com - Investing.com Nigeria
Oppenheimer maintains BioMarin stock Outperform with $98 target - Investing.com
Joshua Grass, John Kelly, and Lauren Daniel Join 5AM Ventures - GlobeNewswire Inc.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - Longview News-Journal
BioMarin Earnings Preview: New CEO Alexander Hardy to Reveal First Quarter Strategy Shift - Stock Titan
Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction - Benzinga
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo
With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals
Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com
Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com
Quality Management Process LeadSan RafaelBioMarin Pharmaceutical - Ladders
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
5.02%
자본화:
|
볼륨(24시간):